12.89
12.89 (-0.21%)
As of Jun 14, 2022
Related Stories
- Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
- Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
- Special Opportunities Fund Reaches Settlement With Delaware Enhanced Global Dividend and Income Fund
- Special Opportunities Fund, Inc. Annual Stockholders Meeting
- Analog Devices Announces World’s First Long-Reach, Single-pair Power over Ethernet (SPoE) Solutions for Smart Building and Factory Automation